Sigyn Therapeutics (OTCMKTS:SIGY) Announces Quarterly Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) issued its earnings results on Thursday. The company reported ($0.42) EPS for the quarter, Zacks reports.

Sigyn Therapeutics Trading Up 6.4%

OTCMKTS SIGY opened at $0.03 on Friday. The firm has a market cap of $63,500.00, a price-to-earnings ratio of -0.01 and a beta of -0.08. Sigyn Therapeutics has a 1-year low of $0.01 and a 1-year high of $5.00. The company has a 50 day moving average of $0.04 and a 200-day moving average of $0.29.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.